Los Angeles-Area A2 Biotherapeutics (www.a2bio.com) announced the closing of its $71.5M Series B financing round to fund the advancement of its Tmod (engineered T-cell module) platform that reportedly combines activating and blocking mechanisms to kill tumor cells and protect normal cells.
and related near-term product candidates.  Series B investors include The Column Group, Vida Ventures, Samsara BioCapital, Nextech Invest, Casdin Capital, Euclidean Capital, UC Investments (Office of the Chief Investment Officer of the Regents) and Hartford HealthCare Endowment. Here are links to related news stories.

https://www.businesswire.com/news/home/20201006005044/en/A2-Biotherapeutics-Closes-71.5M-Series-B-to-Begin-Clinical-Development-of-Its-Potentially-Transformative-Selective-Tumor-Cell-Therapeutics

https://www.prnewswire.com/news-releases/a2-biotherapeutics-closes-71-5m-series-b-to-begin-clinical-development-of-its-potentially-transformative-selective-tumor-cell-therapeutics-301145221.html

Print:
Email this postTweet this postLike this postShare this post on LinkedIn
Photo of Dan Shores Dan Shores

Dan Shores is a Partner at Rothwell Figg.  Dan is a dedicated patent lawyer and strategist who believes in his clients and the power of their ideas. He focuses on serving biotech, medical device, energy, software, cybersecurity, and other technology-based companies and understands …

Dan Shores is a Partner at Rothwell Figg.  Dan is a dedicated patent lawyer and strategist who believes in his clients and the power of their ideas. He focuses on serving biotech, medical device, energy, software, cybersecurity, and other technology-based companies and understands the myriad of challenges that such companies face when breaking through and establishing themselves in their respective markets. Dan works with clients to build robust patent portfolios, protect trade secrets, negotiate strategic collaborations, conduct due diligence and landscape investigations, and prepare for success in funding rounds and exits. An engineer by education, and having extensive experience in transactional, litigation, procurement, and strategic counseling matters for technology-based companies, Dan is a problem-solver who excels at deciphering key translational aspects of a broad array of technologies to maximize leverage in the context of clients’ desired implementation of such technologies whether as participants in dynamic markets or as first movers.

Dan has served companies utilizing the following technologies (without limitation): mRNA therapies; lipid nanoparticle delivery technologies; genetically engineered swine and organs for xenotransplantation; artificial intelligence for drug discovery; CAR-T therapies; oligonucleotide development; pharmaceutical treatment of rhinitis with levocetirizine; pharmaceutical treatment of hepatitis B with telbivudine; genetically-modified cotton seed; fiber-optic probes for tissue investigation; implantable glucose-sensing devices; high throughput genetic seed-chipping technology; cybersecurity threat assessment platforms; interactive media systems for healthcare institutions; artificial intelligence (various applications); identification systems for cable-based medical devices; identification of digital positions of interest on media items; heat-treated glass with multilayer low-emissivity coatings; automotive and agricultural equipment; pressure-sensitive adhesives; three dimensional printing of buildings and other structures; and integrated electronic securities marketplace systems.

Dan is a registered patent attorney licensed to practice before the United States Patent and Trademark Office, and is admitted to practice law in Massachusetts and in the District of Columbia. He is a member of the bars of the Supreme Court of the United States, United States Court of Appeals for the Federal Circuit, and United States District Court for the District of Massachusetts. Dan lives in Boston with his wife Lindsay and their two English Bulldogs Jarves and Rosie.

Read more about Dan ShoresDan's Linkedin Profile
Show more Show less
Related Posts
 The Current mRNA/LNP Patent Litigation Landscape
August 24, 2022
 Merck and Orna Therapeutics Join Forces in Circular RNA Collaboration
August 18, 2022
People communication network concept. Social media.
Increased Innovation in Decentralized Social Networks Space Spurred By Ownership Uncertainty of Traditional Platforms
June 14, 2022